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INTRODUCTION
For metastatic renal cell carcinomas (RCC), palliative radio-
therapy is reported to be effective in providing the patient
with symptom relief (1). However, RCC has historically been
known to be resistant to conventional radiotherapy (2). RCC
radioresistance is attributed to the slow regression of the tumor
after radiotherapy (3). Therefore, radiosurgery has been per-
formed to overcome the resistance of metastatic brain tumors
to treatment (4). Radiosurgery is not easily applicable to extra-
cranial tumors due to the limitation of immobilization and
the potentially significant complications it may cause. Recent-
ly, intensity-modulated radiotherapy (IMRT) was developed
and widely used in the clinic to deliver high doses to tumors
while preserving the adjacent normal tissue. We report here
that radioresponsiveness could be obtained in gross tumors
originating from RCC, through IMRT by delivering a total
dose of 60 Gy at 2.5 Gy fraction. This dosage was larger than
that used in conventional fractionation (1.8-2.0 Gy). To our
knowledge, this is the first report to show that renal fossa
recurrence was salvaged successfully by IMRT. 
CASE REPORT
A 56-yr-old female patient was referred with a mass in
her kidney that was detected on ultrasonography during a
regular health screen. Left RCC was detected by computed
tomography (CT) (Fig. 1A). CT also revealed an osteolytic
lesion in the left-lower ischial bone. In the whole-body bone
scan, focal hot uptakes were detected in the left acetabulum
and left anterior ilium as well as in the left ischium (Fig.
1B). A biopsy performed on the left ischial bone confirmed
metastasis. The possibility that the hot uptake of the left
acetabulum could be attributed to arthritic changes was high.
However, it was difficult to rule out metastasis in the focal
hot uptake of the left-anterior-ilium lesion. Radical nephrec-
tomy was first performed on the left kidney (Fig. 1C). Histo-
logically, the tumor showed conventional RCCa with Fuhr-
man nuclear grade 4 and focal sarcomatoid differentiation
(pT1N0) (Fig. 1D, E). Seven lymph node samplings were
negative. 
After surgery, IMRT using simultaneously integrated boost
(SIB-IMRT) was planned for the left pelvic bone (Fig. 2A).
SIB-IMRT prescribes a different dose to a different target
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Hypofractionated High-Dose Intensity-Modulated Radiotherapy 
(60 Gy at 2.5 Gy per Fraction) for Recurrent Renal Cell Carcinoma: 
A Case Report
A patient with renal cell carcinoma (RCC) developed synchronous bone metasta-
sis with metachronous relapses to the bone and renal fossa. The primary lesion
was initially removed surgically, and the metastatic bone lesions and locally recur-
rent tumours were treated by a high-fractional dose and high-total-dose intensity-
modulated radiotherapy (IMRT, 60 Gy at 2.5 Gy per fraction) without significant
side effects. All the grossly relapsed tumors underwent complete remission (CR)
within a short time after IMRT. To date, CR has been maintained for more than
two years. This case study reports the successful treatment of radioresistant RCC
using a new scheme that involves a fractionation regimen with a high precision
radiotherapy.
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volume simultaneously. The basis of the treatment protocol
was an irradiation in 24 fractions, with a total dose of 60 Gy
(2.5 Gy per fraction) to the region of the macroscopic tumors,
including the left ischium confirmed by biopsy and the possi-
ble metastatic lesion, a small, round osteoblastic lesion on
the left anterior ilium. The protocol also involved a dose of
45 Gy (1.9 Gy per fraction) to the region of low-risk sub-
clinical disease, including the rest of the left pelvic bone and
excluding the high-dose region. A unique feature of the pre-
sent SIB strategy is that irradiation of the microscopic tumors
remains the same as in the conventional treatments, where-
as the relapsed gross tumors are irradiated using a hypofrac-
tionation scheme. The IMRT plans were generated by the
Corvus treatment planning system (NOMOS Corporation,
Sewickley, PA, U.S.A.). The ischial bone gross tumor had
almost disappeared by the follow-up study one month after
IMRT (Fig. 3A).
Five months after IMRT to the left pelvic bone, new lesions
that were suspected to be metastatic were detected in the
right pelvis, and multiple conglomerated hypervascular solid
masses had developed in the renal fossa. In addition, in the
vicinity of the 9th-left-rib costochondral junction, an expan-
sile mass was detected on the rib. As such, a second IMRT
was performed on the newly detected metastasis and on the
local recurrent lesions (Fig. 2B). Until two months after the
second IMRT, systemic anti-cancer treatment had not been
performed because of the patient’s refusal. In the follow-up
study that was conducted one month after radiation therapy
alone, the rib expansile mass and the locally recurrent renal
fossa mass underwent complete remission (CR) (Fig. 3). The
patient tolerated both sessions of SIB-IMRT very well with-
out any significant side effects or interruption.
After experiencing CR of all the grossly relapsed tumours,
the patient accepted the systemic anti-cancer treatment.
Hence, interferon-alpha systemic therapy (6,000,000 units,
three times a week) was administered for four months. Sub-
sequently, six months after the second IMRT, a small nodule,
which had developed in the lower left lung approximately six
months after surgery and thought to be merely an inflam-
matory nodule, showed a slight increase in size. Hence, under
Fig. 1. (A) Abdomino-pelvic CT revealing a heterogeneous mass lesion (approximately 7 cm in size) on the left kidney midpole extending
to the renal pelvis. (B) Whole-body bone scan performed for staging workup, showing a focus of increased uptake in the left ischium, left
anterior ilium, and left acetabulum. (C) Gross appearance: a circumscribed tumor in the midpole of the kidney shows a variegated cut
surface composed of golden yellow and pinkish parenchyma and areas of necrosis. (D) This tumor is predominantly composed of con-
ventional RCC (right side) and a small portion of sarcomatoid RCC (left side). The conventional RCC component has clear cells inter-
spersed with abundant, thin-walled blood vessels, while the sarcomatoid component consists of interlacing bundles of spindle cells with
pleomorphic nuclei. (E) Metastatic carcinoma on the ischial bone (H&E, ×200); most metastatic carcinoma are the sarcomatoid compo-
nent of RCC.
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the suspicion of clinical metastasis (a histological test was
performed, but failed to provide a definitive diagnosis of the
condition), the patient is currently undergoing a clinical drug
trial with Sunitinib (Sutent), given orally at a dose of 50 mg/
day on a four-week-on/two-week-off schedule. Until now,
the patient’s locally and distantly relapsed lesions, which were
treated with SIB-IMRT, have maintained their CR condition
(Fig. 3) for more than two years.
Fig. 2. Dose distribution for the SIB-IMRT plans. (A) The 1st IMRT SIB delivers 60 and 45.06 Gy in 24 fractions to the gross metastatic
tumors (blue) and the rest of the left pelvic bone (violet). (B) The 2nd IMRT SIB also delivers 60 Gy in 24 fractions to the gross renal
fossa recurrent tumor (blue) and the left rib mass in the vicinity of the left 9th costochondral junction (blue). The isodose lines of 60,
55, 50, 45, 30, and 20 Gy are shown.
A B
Fig. 3. Metastatic bony lesions to the left ischium (A), the left rib in the vicinity of the left 9th costochondral junction (B), and the renal fossa
recurrent tumor (C). a-1, b-1, and c-1 reveal pre-treatment gross tumors. a-2, b-2, and c-2 show SIB-IMRT differential-dose distribution,
which is highly conformed to the gross and microscopic tumors on each site. a-3, b-3, and c-3 are follow-up images showing complete
disappearance 1-3 months after IMRT to each site. a-4 and b-4 show the re-ossification of the metastatic bones 20 months and 25 months
after IMRT. c-4 also shows complete remission of renal fossa, which has been maintained 25 months after IMRT.
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DISCUSSION
Although the rib lesion in the vicinity of the left 9th cos-
tochondral junction might be salvaged even by 3D-confor-
mal radiotherapy, IMRT could be essential to deliver high
doses of radiation to the renal fossa close to the bowel with-
out side effects. It could also be extremely useful for selec-
tively delivering high dose radiation to the gross pelvic bone
tumor and low dose radiation to the microscopic tumor in
the remaining pelvis by the SIB technique. As a result, CRs
were gained in all the gross RCC by high-precision IMRT
alone, without any significant side effects.
More importantly, 60 Gy at 2.5 Gy per fractional treat-
ment cleared all the gross lesions within 2-3 months, where-
as using conventional fractionation (30-40 Gy) we generally
experience minimal changes in the tumor size. We are plan-
ning to prove the efficacy of this prescription regimen in the
prospective setting. 
To our knowledge, this report is the first to show that in a
renal fossa recurrence case, treatment with IMRT alone could
lead to CR. Furthermore, the recurrent disease in the renal
fossa has not been detected in the patient during the subse-
quent two years. After radical nephrectomy, renal fossa recur-
rence is very rare, but its prognosis is poor. Previous studies
reporting local recurrence indicate many low-risk T1 cases.
In all cases, the development of Fuhrman grades of tumors
as well as various histological subtypes occurred. As such,
the cause of renal fossa recurrence could not be determined
(5-7). Instead, it could only be due to the biological hetero-
geneity of each tumor. Since it is very rare, it is usually
described in case studies. Most reports outline the benefits
of using an aggressive surgical approach for treatment (6, 8,
9). The optimal management has to be established on more
experiences, considering side effects and treatment outcome
of each modality including surgery, immunochemotherapy
(ICT), and IMRT simultaneously (6, 8-10). The high-dose
precision radiation therapy by IMRT may become the most
important modality for the local control of RCC, overshad-
owing conventional radiation therapies. 
To conclude, in metastatic and locally recurrent RCC, the
IMRT technique, which prescribes a high-total-dose with a
higher fractional dose than conventional treatment, gains
CR in a short time, and maintains a sufficient disease-free
state. IMRT also allows maximal preservation of the adja-
cent normal tissue. Thus, SIB-IMRT could be the most effec-
tive modality for the local control of RCC in patients that
have locally and distantly relapsed gross tumors. In addi-
tion, SIB-IMRT allows RCC patients to preserve their qual-
ity of life with minimal side effects from the treatment.
REFERENCES
1. DiBiase SJ, Valicenti RK, Schultz D, Xie Y, Gomella LG, Corn
BW. Palliative irradiation for focally symptomatic metastatic renal
cell carcinoma: support for dose escalation based on a biological
model. J Urol 1997; 158: 746-9. 
2. Wronski M, Maor MH, Davis BJ, Sawaya R, Levin VA. External
radiation of brain metastases from renal carcinoma: a retrospective
study of 119 patients from the M. D. Anderson Cancer Center. Int J
Radiat Oncol Biol Phys 1997; 37: 753-9. 
3. Fertil B, Malaise EP. Intrinsic radiosensitivity of human cell lines is
correlated with radioresponsiveness of human tumors: analysis of
101 published survival curves. Int J Radiat Oncol Biol Phys 1985;
11: 1699-707. 
4. Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD.
Radiosurgery in patients with renal cell carcinoma metastasis to the
brain: long-term outcomes and prognostic factors influencing sur-
vival and local tumor control. J Neurosurg 2003; 98: 342-9. 
5. Gogus C, Baltaci S, Beduk Y, Sahinli S, Kupeli S, Gogus O. Isolat-
ed local recurrence of renal cell carcinoma after radical nephrecto-
my: experience with 10 cases. Urology 2003; 61: 926-9. 
6. Itano NB, Blute ML, Spotts B, Zincke H. Outcome of isolated renal
cell carcinoma fossa recurrence after nephrectomy. J Urol 2000;
164: 322-5. 
7. Schrodter S, Hakenberg OW, Manseck A, Leike S, Wirth MP. Out-
come of surgical treatment of isolated local recurrence after radical
nephrectomy for renal cell carcinoma. J Urol 2002; 167: 1630-3. 
8. Master VA, Gottschalk AR, Kane C, Carroll PR. Management of
isolated renal fossa recurrence following radical nephrectomy. J
Urol 2005; 174: 473-7.
9. Tanguay S, Pisters LL, Lawrence DD, Dinney CP. Therapy of local-
ly recurrent renal cell carcinoma after nephrectomy. J Urol 1996;
155: 26-9. 
10. Figlin RA, Abi-Aad AS, Belldegrun A, deKernion JB. The role of
interferon and interleukin-2 in the immunotherapeutic approach to
renal cell carcinoma. Semin Oncol 1991; 18 (5 Suppl 7): 102-7. 
